TransMedics Group, Inc. $TMDX Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 342,791 shares of the company’s stock after selling 8,558 shares during the quarter. TransMedics Group accounts for about 1.1% of Emerald Advisers LLC’s investment portfolio, making the stock its 28th biggest position. Emerald Advisers LLC’s holdings in TransMedics Group were worth $34,077,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the third quarter valued at about $29,000. Allworth Financial LP grew its stake in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. Parallel Advisors LLC increased its holdings in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the last quarter. Ascentis Independent Advisors purchased a new stake in TransMedics Group during the 1st quarter worth approximately $30,000. Finally, North Star Investment Management Corp. acquired a new position in shares of TransMedics Group in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $75.74 on Tuesday. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company’s 50-day moving average price is $71.02 and its 200 day moving average price is $105.87. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of 17.21 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 earnings per share. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMDX. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Wednesday, July 1st. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Piper Sandler decreased their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $134.50.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.